Discussion on whether Lemborexant can completely cure insomnia

From the perspective of drug positioning, Lemborexant is not a drug designed to "cure insomnia", but is a modern sleep aid treatment option for improving sleep structure and sleep quality. Insomnia itself is not a single disease, but a comprehensive problem closely related to neuroregulation, psychological state, life rhythm and physical health. This also determines that it is difficult for any single drug to fundamentally "cure" all types of insomnia.

Leborexan is an oral tablet, usually taken as needed, no more than once a day, and is recommended to be used before bed. Judging from clinical practice experience, if you do not take it with meals or avoid taking it immediately after meals, the drug will take effect relatively quickly and help you fall asleep more smoothly. Some patients can experience a shortened time to fall asleep, fewer nighttime awakenings, and improved overall sleep continuity within 7 to 10 days after starting to take it. This relatively clear early improvement experience makes many patients mistakenly believe that "insomnia has been cured." However, from a medical point of view, this is more of a symptom control effect.

In the concept of insomnia treatment, Lebraxen is closer to a "sleep regulator" rather than a tool to eradicate the cause. It helps the body enter and maintain sleep more easily by regulating the activity of the brain's wakefulness system, but it does not directly change the underlying causes of insomnia, such as long-term anxiety, depression, circadian rhythm disorders, or the effects of chronic diseases. Therefore, once the medication is stopped, some patients may still have sleep problems again if the relevant triggers still exist.

If your sleep condition does not improve within 7 to 10 days after taking Lebraxant, or if your sleep quality decreases or your mood or behavior changes during treatment, you should communicate with your doctor in time. This reminder itself illustrates that Lebrasin is not a “one-and-done” solution, but rather a tool that needs to be used dynamically during assessment and follow-up.

Reference materials:https://medlineplus.gov/druginfo/meds/a620039.html